Last reviewed · How we verify
IV Acetaminophen (Treatment A)
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Management of mild to moderate pain, Reduction of fever, Management of moderate pain with opioids.
At a glance
| Generic name | IV Acetaminophen (Treatment A) |
|---|---|
| Also known as | OFIRMEV |
| Sponsor | Mallinckrodt |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX) enzymes |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Acetaminophen works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering pain perception and body temperature set point. The intravenous formulation provides rapid systemic delivery for faster onset of analgesia and antipyresis compared to oral routes. It does not have significant peripheral anti-inflammatory activity like NSAIDs.
Approved indications
- Management of mild to moderate pain
- Reduction of fever
- Management of moderate pain with opioids
Common side effects
- Nausea
- Vomiting
- Headache
- Infusion site pain
- Hypotension
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Acetaminophen (Treatment A) CI brief — competitive landscape report
- IV Acetaminophen (Treatment A) updates RSS · CI watch RSS
- Mallinckrodt portfolio CI